Date: 2012-07-03
Type of information: Licensing agreement
Compound: EB66® cell line
Company: Vivalis (France) Merck Animal Health - Merck&Co (USA)
Therapeutic area: Veterinary medicine
Type agreement: licensing
R&D
Action mechanism:
Disease:
Details: Vivalis has executed a new research license agreement with Merck Animal Health (known as MSD Animal Health outside the USA and Canada) to evaluate the production of additional animal vaccine candidates using Vivalis’ EB66® cell line. In 2009, Merck Animal Health signed an EB66® commercial license agreement for the production of a poultry vaccine. Terms of the agreement were not disclosed.
Financial terms:
Latest news:
